Escitalopram for agitation in Alzheimer's disease (S‐CitAD): Methods and design of an investigator‐initiated, randomized, controlled, multicenter clinical trial

Abstract

S-CitAD will provide information about a practical, immediately available approach to treating agitation in patients with AD. S-CitAD may become a model of how to evaluate and predict treatment response in patients with AD and agitation as a neuropsychiatric symptom (ClinicalTrials.gov Identifier: NCT03108846).